Hiroo Ishida

1.2k total citations
70 papers, 877 citations indexed

About

Hiroo Ishida is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Hiroo Ishida has authored 70 papers receiving a total of 877 indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 21 papers in Molecular Biology. Recurrent topics in Hiroo Ishida's work include Lung Cancer Treatments and Mutations (21 papers), Colorectal Cancer Treatments and Studies (19 papers) and Cancer therapeutics and mechanisms (15 papers). Hiroo Ishida is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Colorectal Cancer Treatments and Studies (19 papers) and Cancer therapeutics and mechanisms (15 papers). Hiroo Ishida collaborates with scholars based in Japan, United States and France. Hiroo Ishida's co-authors include Yasutsuna Sasaki, Ken‐ichi Fujita, Takashi Hirose, Tohru Ohmori, Sojiro Kusumoto, Toshimitsu Yamaoka, Takao Shirai, Tsukasa Ohnishi, Yu Sunakawa and Tomohide Sugiyama and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Clinical Cancer Research and Optics Letters.

In The Last Decade

Hiroo Ishida

67 papers receiving 861 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hiroo Ishida Japan	19	544	328	278	102	76	70	877
Sander Bins Netherlands	17	688 1.3×	324 1.0×	376 1.4×	117 1.1×	53 0.7×	59	1.2k
Sojiro Kusumoto Japan	19	522 1.0×	485 1.5×	349 1.3×	117 1.1×	36 0.5×	49	1.0k
Jeroen J. M. A. Hendrikx Netherlands	17	527 1.0×	193 0.6×	221 0.8×	55 0.5×	97 1.3×	57	939
Rossana Roncato Italy	18	395 0.7×	159 0.5×	284 1.0×	144 1.4×	53 0.7×	52	907
Carlos Jamis‐Dow United States	18	354 0.7×	437 1.3×	305 1.1×	74 0.7×	128 1.7×	23	1.2k
Jill Kolesar United States	19	329 0.6×	139 0.4×	296 1.1×	146 1.4×	55 0.7×	68	948
Daniel Mulkerin United States	18	670 1.2×	229 0.7×	366 1.3×	89 0.9×	51 0.7×	79	1.2k
E. Boven Netherlands	11	503 0.9×	116 0.4×	308 1.1×	63 0.6×	46 0.6×	25	770
Justin D. Floyd United States	11	475 0.9×	178 0.5×	121 0.4×	72 0.7×	42 0.6×	17	846
Yon‐Dschun Ko Germany	19	277 0.5×	151 0.5×	444 1.6×	140 1.4×	40 0.5×	63	917

Countries citing papers authored by Hiroo Ishida

Since Specialization

Citations

This map shows the geographic impact of Hiroo Ishida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroo Ishida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroo Ishida more than expected).

Fields of papers citing papers by Hiroo Ishida

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroo Ishida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroo Ishida. The network helps show where Hiroo Ishida may publish in the future.

Co-authorship network of co-authors of Hiroo Ishida

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroo Ishida. A scholar is included among the top collaborators of Hiroo Ishida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroo Ishida. Hiroo Ishida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Murase, Remi, et al.. (2024). Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer. Cancer Chemotherapy and Pharmacology. 94(1). 57–66. 1 indexed citations

Arai, Jun, Ken‐ichi Fujita, Kaku Goto, et al.. (2022). Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer. BMC Cancer. 22(1). 428–428. 5 indexed citations

Ishida, Hiroo, Yutaro Kubota, Masataka Nakano, et al.. (2021). Characteristics of miRNA-SNPs in healthy Japanese subjects and non-small cell lung cancer, colorectal cancer, and soft tissue sarcoma patients. Non-coding RNA Research. 6(3). 123–129. 1 indexed citations

Kubota, Yutaro, Hiroo Ishida, Ryotaro Ohkuma, et al.. (2021). Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure. Cancer Chemotherapy and Pharmacology. 88(3). 543–553. 8 indexed citations

Izawa, Naoki, Takashi Kawaguchi, Tempei Miyaji, et al.. (2020). Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1–4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy. BMJ Open. 10(12). e041737–e041737. 1 indexed citations

Mori, Daiki, Hiroo Ishida, Tadahaya Mizuno, et al.. (2020). Alteration in the Plasma Concentrations of Endogenous Organic Anion–Transporting Polypeptide 1B Biomarkers in Patients with Non–Small Cell Lung Cancer Treated with Paclitaxel. Drug Metabolism and Disposition. 48(5). 387–394. 29 indexed citations

Yamaoka, Toshimitsu, Tohru Ohmori, Motoi Ohba, et al.. (2017). Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation. Molecular Cancer Research. 15(7). 915–928. 41 indexed citations

Fujita, Ken‐ichi, Hiroo Ishida, Yutaro Kubota, & Yasutsuna Sasaki. (2017). Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology. Current Drug Metabolism. 18(3). 186–198. 24 indexed citations

Yamaoka, Toshimitsu, Tohru Ohmori, Motoi Ohba, et al.. (2016). Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation. Molecular Cancer Therapeutics. 15(12). 3040–3054. 28 indexed citations

10.

Fujita, Ken‐ichi, Yutaro Kubota, Hiroo Ishida, et al.. (2016). Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan. Journal of Pharmaceutical Health Care and Sciences. 2(1). 30–30. 5 indexed citations

11.

Fujita, Ken‐ichi, Kaori Kawara, Kazuya Maeda, et al.. (2015). A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer. Cancer Chemotherapy and Pharmacology. 76(4). 793–801. 13 indexed citations

12.

Ando, Yukio, Kenji Kawada, Ayako Mitsuma, et al.. (2014). Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors. Cancer Chemotherapy and Pharmacology. 73(4). 673–683. 17 indexed citations

13.

Sasaki, Yasutsuna, Keisuke Miwa, Keishi Yamashita, et al.. (2014). A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors. Investigational New Drugs. 33(2). 332–340. 25 indexed citations

14.

Hirose, Takashi, Hiroo Ishida, K Okuda, et al.. (2013). Clinical Benefit of 2ND EGFR-TKI Retreatment on Overall Survival in Patients with Advanced Non-Small Cell Lung Cancer. Annals of Oncology. 24. ix43–ix43. 1 indexed citations

15.

Sunakawa, Yu, Ken‐ichi Fujita, Wataru Ichikawa, et al.. (2012). A Phase I Study of Infusional 5-Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan in Japanese Patients with Advanced Colorectal Cancer Who Harbor UGT1A1*1/*1,*1/*6 or *1/*28. Oncology. 82(4). 242–248. 17 indexed citations

16.

Sunakawa, Yu, Wataru Ichikawa, Ken‐ichi Fujita, et al.. (2010). UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. Cancer Chemotherapy and Pharmacology. 68(2). 279–284. 33 indexed citations

17.

Shirai, Takao, Takashi Hirose, Hiroo Ishida, et al.. (2006). Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer. Lung Cancer. 52(2). 181–187. 13 indexed citations

18.

Hirose, Takashi, et al.. (2003). Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer. Lung Cancer. 40(3). 333–338. 31 indexed citations

19.

Otani, Keisuke, et al.. (1990). [Radiation-induced malignant skin tumors in the hands of five doctors].. PubMed. 36(2). 224–8. 2 indexed citations

20.

Ishida, Hiroo, Hiroki Tashiro, M. Watanabe, et al.. (1990). Measurement of Inhibin Concentrations in Men: Study of Changes after Castration and Comparison with Androgen Levels in Testicular Tissue, Spermatic Venous Blood, and Peripheral Venous Blood. The Journal of Clinical Endocrinology & Metabolism. 70(4). 1019–1022. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact